Objective: It has been reported that crocodile blood contains potent antibacterial and antiviral properties. However, its effects on HIV-1 infection remain unknown.
Design: We obtained blood from saltwater crocodiles to examine whether serum or plasma could inhibit HIV-1 infection. We purified plasma fractions then used liquid chromatography-mass spectrometry to identify the inhibitory protein factor(s). We then analyzed the ability of recombinant proteins to recapitulate HIV-1 inhibition and determine their mechanism of action.
Methods: Crocodylus porosus plasma was tested for inhibition of Jurkat T-cell HIV-1 infection. Inhibitor(s) were purified by reverse-phase chromatography then identified by protein liquid chromatography-mass spectrometry. Anti-HIV-1 activity of purified plasma or recombinant proteins were measured by p24 enzyme-linked immunosorbent assay and luciferase readouts, and mechanism of action was determined by measuring HIV-1 RNA, cDNA and transcription (using 1G5 cells).
Results: Crocodile plasma contains potent inhibitors of HIV-1IIIB infection, which were identified as histones. Recombinant human histones H1 and H2A significantly reduced HIV-1JR-FL infection (IC50 of 0.79 and 0.45 μmol/l, respectively), whereas H4 enhanced JR-FL luciferase activity. The inhibitory effects of crocodile plasma, recombinant H1 or recombinant H2A on HIV-1 infection were during or post-viral transcription.
Conclusion: Circulating histones in crocodile blood, possibly released by neutrophil extracellular traps, are significant inhibitors of HIV-1 infection in-vitro. Extracellular recombinant histones have different effects on HIV-1 transcription and protein expression and are downregulated in HIV-1 patients. Circulating histones may be a novel resistance factor during HIV-1 infection, and peptide versions should be explored as future HIV-1 therapeutics that modulate viral transcription.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/QAD.0000000000001159 | DOI Listing |
Clin Infect Dis
December 2024
Université Paris Cité, Inserm, IAME, F-75018, Paris, France.
Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with multi-drug resistant HIV-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug-resistance associated mutations.
View Article and Find Full Text PDFAIDS Res Ther
December 2024
Jennifer Tiu, ACTG Network Coordinating Center, Bethesda, USA.
Background: Cervical cancer is a common cancer worldwide, with > 85% of deaths occurring in Lower- and Middle-Income Countries where resources for screening programs are limited. Women living with HIV (WLHIV) are at increased risk. HPV test-and-treat is a screening strategy where women with HPV are offered ablative treatment of the cervix to reduce the risk of invasive cancer.
View Article and Find Full Text PDFClin Infect Dis
December 2024
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Background: Most research on HIV-1 viremia and cancer risk is from high-income countries. We evaluated the association between HIV-1 viremia and the risk of various cancer types among people with HIV (PWH) in South Africa.
Methods: We analysed data from the South African HIV Cancer Match study, based on laboratory measurements from the National Health Laboratory Services and cancer records from the National Cancer Registry from 2004-2014.
Cureus
November 2024
Microbiology, Retired-Private Practice, Chennai, IND.
The accurate quantification of nuclear factor Kappa B p65 (NF-κB p65) is critical for understanding inflammatory mechanisms, especially in HIV-1 infected individuals, where NF-κB p65 contributes to chronic immune activation. Conventional methods such as enzyme-linked immunosorbent assay (ELISA) and western blotting are limited in terms of sensitivity and reproducibility. This study aimed to devise a standardized real-time quantitative polymerase chain reaction (RT-qPCR) assay for NF-κB p65 using specifically designed primers and a probe.
View Article and Find Full Text PDFMed J Armed Forces India
December 2024
Brig Med, HQ 2 Corps, C/o 56 APO, India.
34 years old male from north-east India, a known case of retroviral disease, presented with shortness of breath and significant weight loss and was found to have pancytopenia, skin lesions, organomegaly, generalized lymphadenopathy, cavitary lung disease with very low CD4 counts. He failed to improve on empirical antitubercular therapy and further evaluation revealed features of disseminated talaromycosis on bone marrow studies. We hereby present an interesting case of a systemic fungal disease in the setting of advanced HIV infection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!